Lacrimal Sac Tumors: A Case Series
Ocular Oncology and Pathology · 2022 · 8 (1) · 42-51
DOI: 10.1159/000520086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 18.10.2021. Verfasst von Syeed Mehbub Ul Kadir und 6 weiteren Autor:innen. Beteiligte Einrichtung: Training and Academy, Sheikh Fajilatunnessa Mujib Eye Hospital and Training Institute, Gopalgonj, Bangladesh. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
The aim of the study was to describe the clinical presentation, management strategies, and outcomes in a case series of primary lacrimal sac tumors.
Methods
This retrospective study was conducted in Sheikh Fajilatunnessa Mujib Eye Hospital and Training Institute, Bangladesh, from July 1 to December 31, 2020, and included all patients who were evaluated, treated, and followed up for at least 6 months from January 2013 to October 2020. One patient developed a recurrence of the adenocarcinoma of the lacrimal sac after 1 year of primary treatment. Patients’ demographic data were analyzed and reviewed from published articles on lacrimal sac tumors. We assessed patients clinically, followed by radiological evaluation. We also analyzed the biopsy technique, treatment modality, and recurrence. An oncologist reviewed all patients to prepare a plan for adjuvant treatment.
Results
Ten patients with lacrimal sac tumors were included in this study. Swelling in the medial canthal region was the most common presenting feature (100%), followed by epiphora (60%) and pain (30%). Open biopsy was preferred over fine-needle aspiration biopsy. Incisional biopsy or complete excisional biopsy was performed for all suspected malignancies. Malignant tumors were found in 7 (70%) cases, and benign tumors in 3 (30%) cases. Non-Hodgkin’s lymphoma (NHL) (40%) was the most common malignant lacrimal sac tumor. Mucosa-associated lymphoid tissue lymphoma was 75%, and diffuse large B-cell lymphoma was 25% among the cases of NHL. Patients with epithelial malignancy were treated with external beam radiation therapy, while NHL patients were treated with chemotherapy (CHOP regimen). Recurrence was noted in 1 case (10%) of epithelial malignancy after 1 year of treatment.
Conclusion
Successful management of lacrimal sac tumors requires a high index of suspicion, as these are fatal tumors, often misdiagnosed as dacryocystitis. Nonepithelial malignancies are more predominant than epithelial malignancies, and hematolymphoid tumors are most frequent.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Training and Academy, Sheikh Fajilatunnessa Mujib Eye Hospital and Training Institute, Gopalgonj, Bangladesh.
- Department of Ocular Oncology and Oculoplasty, Ispahani Islamia Eye Hospital and Institute (IIEHI), Dhaka, Bangladesh.
- Department of Ocular Oncology and Oculoplasty, Chittagong Eye Infirmary and Training Complex (CEITC), Chittagong, Bangladesh.
- Department of Pathology, Northern International Medical College and Hospital, Dhaka, Bangladesh.
- Department of Ophthalmology, Dhaka Medical College, Dhaka, Bangladesh.
- Medical Education, Bangladesh Eye Hospital and Institute, Dhaka, Bangladesh.
Zitieren
APA
Kadir, S. M. U., Rashid, R., Sultana, S., Nuruddin, M., Nessa, M. S., Mitra, M. R., & Haider, G. (2022). Lacrimal Sac Tumors: A Case Series. Ocular Oncology and Pathology, 8(1), 42-51. https://doi.org/10.1159/000520086
Vancouver
Kadir SMU, Rashid R, Sultana S, Nuruddin M, Nessa MS, Mitra MR, et al. Lacrimal Sac Tumors: A Case Series. Ocular Oncology and Pathology. 2022;8(1):42-51. doi:10.1159/000520086
BibTeX
@article{Kadir2022,
author = {Kadir, Syeed Mehbub Ul and Rashid, Riffat and Sultana, Sadia and Nuruddin, Murtuza and Nessa, Mst Sayedatun and Mitra, Mukti Rani and Haider, Golam},
title = {Lacrimal Sac Tumors: A Case Series},
journal = {Ocular Oncology and Pathology},
year = {2022},
volume = {8},
number = {1},
pages = {42--51},
doi = {10.1159/000520086}
}
EUVIMED